Role of Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer
Posted: Wednesday, January 13, 2021
For patients with advanced epithelial ovarian cancer, cytoreductive surgery may offer a survival benefit, according to an article published in Yonsei Medical Journal. However, additional studies are warranted to confirm the efficacy of this treatment in patients with progressive disease after neoadjuvant chemotherapy, explained Myong Cheol Lim, MD, PhD, of the National Cancer Center, Goyang, Korea, and colleagues.
From 2001 to 2016, the medical records of 36 patients with advanced epithelial ovarian cancer who developed progressive disease following neoadjuvant chemotherapy were collected and analyzed. These patients were either treated with cytoreductive therapy (n = 13) or second-line chemotherapy (n = 23). Patients with an Eastern Cooperative Oncology Group performance status greater than 3, concurrent malignancies, or abnormal end-organ function were excluded from the analysis.
The study findings revealed that the rate of overall survival was longer with cytoreductive surgery (19.4 months) than with second-line chemotherapy (7.9 months). However, cytoreductive surgery was the only successful, independent predictive factor for overall survival (hazard ratio = 2.30). In addition, patients with high-grade serous histology demonstrated an association with increased overall survival compared with those who had non–high-grade serous histology. Moreover, 46% of patients who received cytoreductive therapy were able to successfully receive optimal surgical resection.
“There are no guidelines or suggestions about which category of patients develops progressive disease after neoadjuvant chemotherapy. Therefore, the findings of the current study might be helpful,” explained Dr. Lim.
Disclosure: For full disclosures of the study authors, visit eymj.org.